Actively Recruiting
Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer: An Observational Study
Led by Santa Chiara Hospital · Updated on 2025-02-11
3000
Participants Needed
2
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This observational study focuses on men with metastatic castration-resistant prostate cancer (mCRPC) who have a BRCA mutation. Researchers aim to understand overall survival, clinical outcomes, and factors that may predict or influence these results for patients treated with olaparib in real-world clinical settings. The study is designed to gather both retrospective and prospective data from multiple centers. Participants in this study are mCRPC patients receiving olaparib as part of their routine clinical care. Olaparib is given according to standard practice for BRCA-positive patients. There is no placebo or comparison group, as this study observes outcomes from patients on olaparib in everyday use. During the study, researchers will collect information about disease control from treatment start until the last follow-up or death, up to 120 months. They will also monitor biochemical responses, response rates, progression-free survival, and toxicity over an average of one year. This helps to provide a comprehensive picture of how patients respond to olaparib in typical clinical practice.
CONDITIONS
Brief Title
Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- BRCA mutant metastatic castration-resistant prostate cancer patients treated with olaparib in clinical practice
You will not qualify if you...
- Olaparib treatment in a clinical trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - From treatment start until disease progression or death, assessed up to 120 months
Participants receive Olaparib according to clinical practice for BRCA positive metastatic castration-resistant prostate cancer.
Visits occur as part of routine clinical care
Duration - Up to 120 months from treatment start
Participants are monitored for disease control, biochemical response, progression-free survival, and toxicity during and after treatment.
Follow-up visits according to clinical practice
Trial Site Locations
Total: 2 locations
1
Sabrina Rossetti
Naples, Italy
Actively Recruiting
2
Orazio Caffo
Trento, Italy
Actively Recruiting
Research Team
O
Orazio Caffo, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here